Definium Therapeutics, Inc. - Common Shares (DFTX)

22.01
+0.85 (4.02%)
NASDAQ· Last Trade: May 13th, 5:01 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
Definium (DFTX) Q1 2026 Earnings Transcriptfool.com
Definium (DFTX) Q1 2026 Earnings Transcript
Via The Motley Fool · May 7, 2026
Definium Therapeutics (NASDAQ:DFTX) Misses EPS but Pipeline Progress Steals the Spotlightchartmill.com
Via Chartmill · May 7, 2026
These 3 Psychedelic Stocks Activated After Trump's Executive Ordermarketbeat.com
Via MarketBeat · April 27, 2026
Trump Just Fast-Tracked Psychedelic Treatments: 3 Under-the-Radar Stocks That Could Be About to Soarfool.com
Trump is easing approval for psychedelic treatments for mental disorders.
Via The Motley Fool · April 20, 2026
This $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage Namesfool.com
This clinical-stage biopharma targets neurological and psychiatric disorders with a pipeline of novel therapeutics advancing through trials.
Via The Motley Fool · March 18, 2026
Definium (DFTX) Q4 2025 Earnings Call Transcriptfool.com
Definium (DFTX) Q4 2025 Earnings Call Transcript
Via The Motley Fool · February 27, 2026